Steven Seedhouse
Stock Analyst at Raymond James
(3.33)
# 1,010
Out of 4,911 analysts
172
Total ratings
44.91%
Success rate
3.28%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $73 → $77 | $51.99 | +48.11% | 19 | May 13, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $15.59 | +374.56% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $8.28 | +20.77% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $20.01 | +39.93% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $6.66 | +605.71% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.88 | +1,031.73% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $8.62 | +132.02% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $34.17 | +204.36% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $2.16 | +920.79% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $21.63 | +158.90% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $9.74 | +403.34% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.21 | +533.48% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $116.48 | -20.16% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $21.65 | +214.09% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $19.54 | +442.48% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $4.25 | +253.36% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $9.15 | +512.36% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.35 | +4,865.95% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.40 | +325.37% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.65 | +1,233.33% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.12 | +444.87% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.13 | +1,020.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $45.62 | -16.70% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $33.60 | +111.31% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.85 | +171.00% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $26.75 | +42.06% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.74 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.01 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $13.22 | +1,942.36% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $131.40 | - | 2 | Apr 23, 2020 |
Mirum Pharmaceuticals
May 13, 2025
Maintains: Strong Buy
Price Target: $73 → $77
Current: $51.99
Upside: +48.11%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $15.59
Upside: +374.56%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $8.28
Upside: +20.77%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $20.01
Upside: +39.93%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $6.66
Upside: +605.71%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.88
Upside: +1,031.73%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $8.62
Upside: +132.02%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $34.17
Upside: +204.36%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $2.16
Upside: +920.79%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $21.63
Upside: +158.90%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $9.74
Upside: +403.34%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.21
Upside: +533.48%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $116.48
Upside: -20.16%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $21.65
Upside: +214.09%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $19.54
Upside: +442.48%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $4.25
Upside: +253.36%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $9.15
Upside: +512.36%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.35
Upside: +4,865.95%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.40
Upside: +325.37%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.65
Upside: +1,233.33%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.12
Upside: +444.87%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.13
Upside: +1,020.00%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $45.62
Upside: -16.70%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $33.60
Upside: +111.31%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.85
Upside: +171.00%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $26.75
Upside: +42.06%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $14.74
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.01
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $13.22
Upside: +1,942.36%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $131.40
Upside: -